Results 121 to 130 of about 12,447 (257)

Machine Learning for Predictive Modeling in Nanomedicine‐Based Cancer Drug Delivery

Med Research, Volume 2, Issue 1, Page 130-156, March 2026.
The integration of AI/ML into nanomedicine offers a transformative approach to therapeutic design and optimization. Unlike conventional empirical methods, AI/ML models (such as classification, regression, and neural networks) enable the analysis of complex clinical and formulation datasets to predict optimal nanoparticle characteristics and therapeutic
Rohan Chand Sahu, Sanchit Arora, Dinesh Kumar, Ashish Kumar Agrawal   +3 more
wiley   +1 more source

A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim against Streptococcus suis

Frontiers in Pharmacology
Introduction: Streptococcus suis (S. suis) is a zoonotic pathogen threatening public health. Aditoprim (ADP), a novel veterinary medicine, exhibits an antibacterial effect against S. suis.
Kun Mi, Kun Mi, Lei Sun, Lei Sun, Lan Zhang, Lan Zhang, Aoran Tang, Aoran Tang, Xiaoyuan Tian, Xiaoyuan Tian, Yixuan Hou, Yixuan Hou, Lingling Sun, Lingli Huang, Lingli Huang, Lingli Huang   +15 more
doaj   +1 more source

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis. [PDF]

Front Pharmacol, 2023
Reali F, Fochesato A, Kaddi C, Visintainer R, Watson S, Levi M, Dartois V, Azer K, Marchetti L.   +8 more
europepmc   +1 more source

Semi‐Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Paracetamol (PCM) is extensively metabolized in the liver via glucuronidation, sulfation, and oxidation. Although oral and intravenous PCM are commonly used interchangeably, a comprehensive evaluation of PCM metabolism across both routes is lacking.
Cedric Lau, Charlotte van Kesteren, Robert M. Smeenk, Marieke M. Beex‐Oosterhuis, Birgit C. P. Koch, Lingtak‐Neander Chan, Yvonne S. Lin, Anne van Rongen, Catherijne A. J. Knibbe, Alwin D. R. Huitema, Hinke Huisman‐Siebinga   +10 more
wiley   +1 more source

Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment

Frontiers in Pharmacology
IntroductionAll cosmetic ingredients must be evaluated for their safety to consumers. In the absence of in vivo data, systemic concentrations of ingredients can be predicted using Physiologically based Pharmacokinetic (PBPK) models.
A. Najjar, D. Lange, C. Géniès, J. Kuehnl, A. Zifle, C. Jacques, E. Fabian, N. Hewitt, A. Schepky   +8 more
doaj   +1 more source

Assessment and Benchmarking of Model Informed Approaches in Drug Development for Hemoglobinopathies: A Review of Scientific Advices From January 2000 to December 2024

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Despite the fact that modeling and simulation are now recognized as promising innovative methodologies, their use in the context of development of drugs for sickle cell disease and Thalassemia has not yet been reviewed. Considering the challenges of conducting clinical trials for hemoglobinopathies, our work aims at exploring the current ...
Grace Shalom Govere, Jean‐Michel Dogné, Flora Musuamba   +2 more
wiley   +1 more source

Integrated PBPK modelling for PFOA exposure and risk assessment

Environmental Research
Per- and polyfluoroalkyl substances (PFASs) pose significant public health concerns due to their environmental persistence, bioaccumulation, and ubiquitous presence in human biomonitoring (HBM) data, despite regulatory restrictions. This study establishes a deterministic pharmacokinetic model for perfluorooctanoic acid (PFOA), enabling the estimation ...
Achilleas Karakoltzidis, Spyros P. Karakitsios, Catherine Gabriel, Dimosthenis Α. Sarigiannis   +3 more
openaire   +2 more sources

Population Pharmacokinetic–Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Population pharmacokinetic–pharmacodynamic (PK–PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time
Hyun Chul Kim, Jung Sunwoo, Seonghae Yoon, In‐Jin Jang, Jae‐Yong Chung   +4 more
wiley   +1 more source

The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant. [PDF]

Pharmaceutics, 2023
Saldanha L, Vale N.
europepmc   +1 more source

Using PBPK to Simulate Target Biopredictive Dissolution Profiles for Long‐Acting Injectables ‐ Where to Begin With Critical Bioavailability Attributes?

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Long‐acting injectables (LAI) are of increasing interest as they facilitate improved medication adherence and exposure, with target plasma concentration levels maintained over weeks/months. Biopredictive in vitro dissolution tests can aid formulation development of LAIs and guide quality control dissolution testing by facilitating accelerated ...
Hannah Cleary, Nikoletta Fotaki, Tim Persoons, Deirdre M. D'Arcy   +3 more
wiley   +1 more source